

# Pharmacologic Treatment of Perinatal Depression



Mary C. Kimmel, MD\*, Elizabeth Cox, MD, Crystal Schiller, PhD,  
Edith Gettes, MD, Samantha Meltzer-Brody, MD, MPH

## KEYWORDS

• Depression • Peripartum • Mental health • Medication • Treatment considerations

## KEY POINTS

- Clinicians treating pregnant and postpartum women should be familiar with a range of pharmacologic treatment options, gain comfort with prescribing, and know when to consult a mental health provider.
- Treatment decisions should weigh the risks of medication exposure to fetus or infant with the risks of maternal psychiatric illness on the mother and her family.
- Clinicians should communicate to patients that perinatal depression is a treatable medical condition.

## BACKGROUND AND PREVALENCE

Perinatal depression, defined as depressive symptoms occurring either during pregnancy (antenatal depression [AND]) or postpartum (postpartum depression [PPD])<sup>1,2</sup> is exceedingly common and has serious implications when not adequately identified and treated. It has been estimated that between 14% and 23% of women experience AND,<sup>3</sup> and up to 22% of women develop PPD within the first 12 months after delivery.<sup>4</sup> Yet, it has also been estimated that only 30% to 50% of women with AND or PPD are identified in clinical settings, and an even smaller number (14%–16%) receive any treatment for their symptoms.<sup>5</sup>

## CONSEQUENCES OF PERINATAL DEPRESSION

Untreated AND has been associated with increased risks for preeclampsia and preterm birth, as well as the development of numerous chronic health complications in

---

Disclosure Statement: The UNC Department of Psychiatry (S. Meltzer-Brody, M.C. Kimmel) has received research grant support from Sage Therapeutics as a site for their clinical trial of brexanolone. Dr S. Meltzer-Brody has also received research grant support to UNC from Janssen. Department of Psychiatry, University of North Carolina-Chapel Hill, Campus Box 7160, Chapel Hill, NC 27599-7160, USA

\* Corresponding author.

E-mail address: [mary\\_kimmel@med.unc.edu](mailto:mary_kimmel@med.unc.edu)

Obstet Gynecol Clin N Am 45 (2018) 419–440

<https://doi.org/10.1016/j.ogc.2018.04.007>

0889-8545/18/© 2018 Elsevier Inc. All rights reserved.

[obgyn.theclinics.com](http://obgyn.theclinics.com)

the mother, including diabetes, hypertension, and cardiovascular disease.<sup>6–8</sup> Furthermore, untreated AND is one of the greatest risk factors for the development of PPD.<sup>3,9,10</sup> Untreated PPD has been associated with unplanned weaning or lactation failure, toxic stress of the newborn, impaired bonding and attachment, and can adversely affect the mental and emotional health of the child through school-age.<sup>11–19</sup> PPD is often a trigger for onset of a chronic major depressive disorder, with almost 1 in 3 women continuing to struggle with depressive symptoms at least 4 years after delivery.<sup>20</sup> Most important, PPD is considered to be the greatest risk factor for maternal suicide and infanticide.<sup>21</sup>

### **WEIGHING THE RISKS: PSYCHOTROPIC MEDICATION AND PERINATAL DEPRESSION**

The American Psychiatric Association and American Congress of Obstetrics and Gynecology both recommend either psychotherapy or antidepressant medication as first-line treatment for mild to moderate perinatal depression.<sup>22</sup> Many women express concern about the effects of medication on the fetus or nursing infant,<sup>23</sup> and prefer psychotherapy as the initial approach to their depressive symptoms.<sup>23,24</sup> Both cognitive-behavioral therapy and interpersonal therapy are efficacious treatments for mild to moderate perinatal depression.<sup>25–27</sup> A recent metaanalysis demonstrated that therapies with an interpersonal component (eg, interpersonal therapy) lead to the greatest reduction in depressive symptoms.<sup>28</sup> Interpersonal therapy is a particularly good fit for addressing perinatal depression given its:

1. Time-limited nature,
2. Goal of positively impacting interpersonal functioning, including the mother-infant relationship and relationship with the husband or partner, and
3. Focus on increasing social support more broadly, which is critically important for maternal well-being.<sup>29</sup>

Psychotherapy during the perinatal period should be delivered individually whenever possible because it leads to greater improvement in depressive symptoms compared with group therapy.<sup>28</sup> Although there have not been any randomized controlled trials (RCTs) of psychotherapy versus pharmacotherapy for perinatal depression, epidemiologic data suggest that, for moderate to severe symptoms, psychotherapy alone may not be sufficient, and augmentation with pharmacotherapy ought to be considered.<sup>30</sup> For those receiving both psychotherapy and pharmacotherapy, a multidisciplinary, integrated care team, including the prescribing physician and therapist, is critical for monitoring symptoms and working collaboratively to address both the psychosocial<sup>31</sup> and biological<sup>32</sup> aspects of perinatal depression.

When considering medication use in pregnancy, the thoughtful weighing of potential risks of untreated depressive symptoms in both the mother and developing baby compared with the risk of medication exposure is needed. No decision is completely risk free and the goal of treatment is minimization of risk with efficacy of treatment. All psychotropic medications cross the placenta and no psychotropic medication is approved by the US Food and Drug Administration (FDA) for use during pregnancy.<sup>33</sup> Given that gold standard RCTs for pregnant women and psychotropic medications are not available, we rely on data from case reports, case control studies, and administrative databases.<sup>30</sup> Potential risks to the fetus that must be considered include teratogenicity and neonatal toxicity and/or withdrawal, as well as long-term effects on development. When medication is required, often the best choice is the drug that previously demonstrated good efficacy for the individual, although this choice must be balanced against the safety of the particular drug during pregnancy. Medication

should be titrated to the lowest effective therapeutic dose, with a goal of full symptom remission. As pregnancy progresses, higher doses of psychotropic medication may be required owing to the marked changes in plasma volumes and drug clearance rates during pregnancy. Therefore, collaborative interdisciplinary care among obstetrics, psychiatry, and pediatrics is of utmost importance to ensure the best clinical outcomes.

## **SELECTIVE SEROTONIN REUPTAKE INHIBITORS, FIRST-LINE PHARMACOLOGIC TREATMENT**

Selective serotonin reuptake inhibitors (SSRIs) are usually considered first-line pharmacologic treatment agents for perinatal depression, including both depressive and anxiety symptoms.<sup>34</sup> See **Table 1** for a list of SSRIs and specifics around dosing and unique considerations. SSRIs inhibit the reuptake of serotonin at the synaptic cleft, thereby amplifying serotonin signaling in the brain.<sup>35</sup> Efficacy and tolerability of different SSRIs have been largely similar in clinical trials.<sup>36,37</sup>

### ***Small for Gestational Age, Preterm Delivery, and Spontaneous Abortion***

---

There have been conflicting data about SSRI exposure during pregnancy and the potential risk of small for gestational age, preterm delivery, and spontaneous abortion. These risks have been associated with perinatal depression itself and the risk may lie with the illness rather than exposure.<sup>38–40</sup> Liu and colleagues<sup>41</sup> found that children of women who continued antidepressants were at greater risk of psychiatric disorders than women who discontinued antidepressants during pregnancy. Continuation may be a marker for more severe depression.

### ***Teratogenicity***

---

Most current data looking at exposure to all SSRIs show no consistent information to support specific teratogenic risks.<sup>42</sup>

### ***Persistent Pulmonary Hypertension of the Newborn***

---

Previous studies have reported conflicting data about increased risk of persistent pulmonary hypertension of the newborn (PPHN) with SSRI exposure during pregnancy, leading the FDA to revise their warning in 2011 to state that the risk is inconclusive.<sup>43–45</sup> However, the most up-to-date publication examining a cohort of more than 3 million women, and adjusting for potential confounding variables, concluded a very small increased absolute risk for PPHN with SSRI exposure (adjusted odds ratio of 1.28 for SSRIs vs 1.14 for non-SSRIs).<sup>46</sup>

### ***Neonatal Toxicity and/or Withdrawal***

---

With pregnancy exposure to SSRIs, there has been evidence of increased risk for medication withdrawal or poor neonatal adaptation syndrome (PNAS) at the time of delivery.<sup>47,48</sup> PNAS has been estimated to occur in up to 30% of exposed babies and can manifest as a range of symptoms, including irritability, respiratory distress, hypoglycemia, feeding difficulties, increased or decreased tone, sleep disturbance, and, more rarely, seizures, prolonged QT interval, or cardiac arrhythmias.<sup>47</sup> PNAS can present minutes to hours after birth and typically resolves within 1 to 2 days.<sup>49</sup> If present, PNAS is usually mild and transient, without residual issues. The likelihood of PNAS being more severe and requiring more significant intervention may occur in up to 3% of exposed neonates.<sup>50</sup> Some investigators have hypothesized that PNAS may be related to a neurologic phenomenon, rather than simply toxicity or withdrawal

**Table 1**  
**Medications, dosing, and unique considerations**

Generic Name	Trade Name	Dosage Range	Unique Considerations/Indications
<b>SSRIs<sup>a</sup></b>			
Sertraline	Zoloft, Serafem	50–200 mg, <sup>b</sup> increase by 25 mg or 50 mg, for very anxious patients 12.5 mg	Due to half-life small, even negligible amounts transmitted into breast milk.
Fluoxetine	Prozac	20–80 mg, increase by 10 mg or 20 mg	Longer half-life → withdrawal less likely if doses are missed, but also longer to get out of the system if there are adverse effects, likely greater amount in breast milk, thought to be more activating.
Citalopram	Celexa	20–40 mg, increase by 10 mg or 20 mg	FDA Drug Safety Communication that >40 mg could result in a life-threatening heart arrhythmia.
Escitalopram	Lexapro	10–20 mg, <sup>b</sup> increase by 5 mg or 10 mg	
Paroxetine	Paxil, Pexeva, Brisdelle	10–60 mg, increase by 10 mg or 20 mg, CR in 12.5 mg doses	Older data demonstrated potential for a 1.5- to 2.0-fold increase risk in cardiovascular malformations, <sup>141</sup> leading to a 2005 warning. <sup>142</sup> Recent data show no consistent information to support teratogenic risks. <sup>42</sup>
Fluvoxamine	Luvox, Faverin, Fevarin, Floxyfral, Dumyrox	25–150 mg, increase by 25 mg	More often used for treatment of obsessive compulsive disorder.
<b>SNRIs<sup>c</sup></b>			
Venlafaxine	Effexor, Effexor XR	37.5–375.0 mg, increase by 37.5 mg	Older and most data available.
Duloxetine	Cymbalta, Irenka	20–120 mg, increase by 20 mg, 30 mg	
Milnacipran	Savella	100 mg BID–200 mg, increase by 12.5 mg, 25 mg, 50 mg	No studies currently available on use in pregnancy examining neither teratogenic risks nor available data about long-term developmental outcomes.

Desvenlafaxine	Pristiq, Khedezia	25–400 mg	No studies currently available on use in pregnancy examining neither teratogenic risks nor available data about long-term developmental outcomes. No evidence >50 mg is helpful.
<b>Other antidepressants: Their own unique mechanisms of action</b>			
Bupropion	Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, and Forfivo XL	150–450 mg, increase by 150 mg, SR BID dosing	Not to exceed 450 mg owing to an increased risk of seizure, greater concern for seizure in those with a history of seizure or those engaging in purging behaviors. Helpful for smoking cessation <sup>144</sup> and even evidence for lower prematurity risk for smokers. <sup>145</sup> May help ADHD and other addictive disorders, such as overeating.
Mirtazepine	Remeron	15–45 mg, increase by 7.5 mg, 15 mg	Antiemetic effects in addition to antidepressant and anxiolytic effects, <sup>146,147</sup> and helps with sleep and decreased appetite.
Trazodone, nefazodone	Olepto, Desyrel, Serzone	50–400 mg, ½ tablet (25 mg)-100 mg for sleep	Sleep aid <sup>148</sup> at lower dosages, higher dosages more antidepressant affects. No differences in the rate of major malformations. <sup>93</sup>
<b>Tricyclic TCAs<sup>d</sup></b>			
Desipramine, nortriptyline	Norpramin, Pamelor, Aventyl	Dose varies for each TCA	Less anticholinergic, so less orthostatic hypotension and constipation, which are common in pregnancy. <sup>149,150</sup>
Amoxapine, imipramine, doxepin, clomipramine, trimipramine, amitriptyline, protriptyline	Asendin, Tofranil, Sinequan, Silenor, Anafranil, Sumontil, Vivactil, Elavil, Vanatrip	Dose varies for each TCA, blood levels are possible to obtain	
<b>MAOIs<sup>e</sup></b>			
Isocarboxazid, phenelzine, selegiline, tranylcypromine	Marplan, Nardil, Emsam, Parnate	Dose varies for each MAOI	Requires special diet, interacts with some medications to cause life-threatening hypertensive crisis.

(continued on next page)

**Table 1**  
(continued)

Generic Name	Trade Name	Dosage Range	Unique Considerations/Indications
Mood stabilizer and antidepressant			
Lamotrigine	Lamictal	>50 mg, start at 25 mg daily and increase by 25 mg every 2 wk to decrease risk of Stevens–Johnson syndrome	Some evidence to use for augmentation in treatment-resistant depression, <sup>151,152</sup> OCD, <sup>153,154</sup> and, therefore, possibly obsessive compulsive symptoms of perinatal depression, <sup>155</sup> and for mood dysregulation and aggressive behaviors of borderline personality disorder, which is often comorbid with depression. <sup>156</sup>
Atypical antipsychotics (ariprazole, quetiapine, olanzapine, risperidone, ziprasidone, lurasidone, paliperidone)	Abilify, Seroquel, Zyprexa, Risperdal, Geodon, Latuda, Invega		With augmentation of depression resulted in modest but statistically significant increased likelihood of remission during 12 wk of treatment compared with switching to bupropion monotherapy <sup>157</sup> ; small study found less likely to have a postpartum mood episode. <sup>158</sup>
Lithium		Increase by 150 mg, 300 mg; Therapeutic blood level 0.4–0.8 for depression augmentation, 0.8–1.2 for mood stabilization	Helpful for monotherapy and augmentation of unipolar depression, <sup>159,160</sup> and postpartum psychosis in addition to Bipolar Disorder. <sup>161</sup> Increases the likelihood of maintaining mood stability during pregnancy and preventing postpartum relapse <sup>162–164</sup> as does immediately restarting postpartum <sup>162,165</sup>

**Abbreviations:** ADHD, attention deficit hyperactivity disorder; BID, 2 times per day; CR, controlled release; FDA, US Food and Drug Administration; MAOI, monoamine oxidase inhibitor; OCD, obsessive–compulsive disorder; SNRI, Serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; XR, extended release.

<sup>a</sup> All treat depression and anxiety, higher dosages needed for anxiety, Black Box warning for use in children secondary to an increased risk of suicidal thoughts at initiation (still used to treat depression, anxiety, which will decrease risk of suicide), increase dosage for 1 week for menses for premenstrual mood worsening or anxiety.

<sup>b</sup> Some providers may increase to 250 mg or 30 mg.

<sup>c</sup> Treat depression and anxiety, and have also shown to be effective treatments for chronic pain.<sup>143</sup>

<sup>d</sup> First discovered in the 1950s, revolutionized treatment of depression and preceded SSRIs,<sup>88</sup> but are associated with higher mortality rates owing to overdose.<sup>89</sup> Helpful for chronic pain.

<sup>e</sup> Gracious and Wisner<sup>90</sup> indicate a use in patients with atypical depression that have not otherwise responded.

from medication.<sup>51</sup> Importantly, tapering medication to avoid PNAS during the third trimester is not advised, because it has not been shown to improve neonatal health or outcomes, and could place the mother at significant risk of worsened symptoms and decline.<sup>51</sup> Breastfeeding may additionally help to minimize or ease any potential serotonin withdrawal symptoms for the infant in the early postpartum period.<sup>52</sup>

### **Long-Term Developmental Outcomes**

The risk for autism spectrum disorders associated with SSRI exposure during pregnancy is controversial. Maternal depression has been found to be potentially neurotoxic, and is a considerable confounding variable.<sup>53</sup> Some studies have shown potential risk for autism spectrum disorders with SSRI exposure<sup>54–56</sup>; however, when adjusted for confounders, including the risk of maternal depression, statistical significance is usually lost.<sup>57–59</sup> Other developmental outcomes that must be considered with perinatal exposure to psychotropic medications include language, growth, and motor development. Review of available data demonstrates no effects of in utero SSRI exposure on head circumference, weight, or length during the first year of life.<sup>60</sup> Examination of the literature on IQ and behaviors of sibling pairs in mother's with and without SSRI exposure during pregnancy showed that the child's IQ was predicted by maternal IQ. Maternal depression has an impact on problematic behaviors in the children.<sup>53</sup> Last, a longitudinal study of the development in children with in utero SSRI exposure found no differences in mental indices; psychomotor scores were mildly lower during the first year of life, and then normalized thereafter.<sup>61</sup>

### **SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, IMPORTANT ALTERNATIVES**

Serotonin norepinephrine reuptake inhibitors (SNRIs), as detailed in **Table 1**, are important alternatives in the treatment of perinatal depressive and anxiety symptoms especially when nonresponsive to SSRIs or if the patient has previously done well on an SNRI.<sup>62,63</sup> SNRIs have a mixed mechanism of action on both serotonin and norepinephrine and have demonstrated good efficacy for treatment refractory depression<sup>35,64</sup> There are fewer data available for SNRI use during pregnancy than for SSRIs.

There has been 1 study in rats showing potential increased risk for cardiac anomalies with venlafaxine exposure in utero.<sup>65</sup> However, available human data, including an aggregate metaanalysis of multidatabase studies including 2.3 million Nordic births, concluded there was no evidence for venlafaxine-related cardiovascular birth defects.<sup>66</sup> The literature comprises a systematic review from 2016, a separate comprehensive appraisal of 29 available studies in 2015, and a 2001 prospective controlled study of 150 exposures to in utero venlafaxine, all of which failed to find an increased rate of major malformations.<sup>67–69</sup> Although there are fewer data with Duloxetine, available studies to date have not found evidence of an apparent increased risk of congenital malformations.<sup>67,69,70</sup>

Data from the Quebec Pregnancy Cohort between 1998 and 2009 investigating risk between SNRI/SSRI exposure and risk for PPHN did not find a statistically significant association; however, the lack of power for the SNRI arm of the study makes the risk assessment ultimately unclear, because there was a small but significantly increased risk with SSRI exposure during the second half of pregnancy in that study.<sup>71</sup>

There is 1 study examining placental transfer of 2 SSRIs (paroxetine and fluoxetine) and 1 SNRI (venlafaxine), which found no pattern of PNAS association with placental transfer of different antidepressants owing to large interindividual variability for each medication<sup>72</sup> However, as with SSRIs, there is potential increased risk for SNRI toxicity or withdrawal/PNAS. Symptom manifestation and presentation for SNRIs is

likely relatively similar.<sup>73</sup> Also, as observed with PNAS management with SSRIs, breastfeeding may help to ease any potential risk for withdrawal symptoms from SNRIs.<sup>73,74</sup>

There are few data available for long-term developmental effects of SNRI exposure in pregnancy. One study examining 62 exposed children ages 3 to 7 years found that IQ was predicted by maternal IQ and not SNRI exposure or duration of SNRI exposure.<sup>53</sup> There is 1 available study looking at desvenlafaxine exposure during pregnancy in Swiss albino mice that found potential risk for increase in anxiety and fearfulness in offspring that could be indicative of possible impact on brain development.<sup>75</sup>

### **BUPROPION AND MIRTAZAPINE, UNIQUE PROPERTIES**

Bupropion inhibits norepinephrine and dopamine reuptake and is the only antidepressant of its kind.<sup>35</sup> The most common side effects are dry mouth, insomnia, and nausea.<sup>76–78</sup> Mirtazapine, a noradrenergic and specific serotonergic antidepressant, has been shown to be comparable with SSRIs in the acute phase treatment of non-pregnancy-related depression.<sup>79,80</sup> See **Table 1** for more on their unique properties and indications.

The literature has been conflicting on risk of bupropion exposure during pregnancy and adverse effects on the fetus. Some studies show no association of first trimester bupropion exposure with congenital or cardiovascular malformations compared with other antidepressants or bupropion exposure outside of the first trimester.<sup>81</sup> Interestingly, the data from this initial report were reanalyzed using more stringent case definitions and concluded that there is a small increased risk, although also acknowledging an inability to account for confounders.<sup>82</sup> Other reports have also shown a positive association between first trimester bupropion use and left outflow tract heart defects, but the magnitude of the observed increased risk was small.<sup>83</sup> More recently, Louik and colleagues<sup>84</sup> in 2014, using data from Slone Epidemiology Center's Case-control Birth Defect Study, concluded that they could not confirm the association with left-sided cardiac defects, but did find an increased risk of ventricular septal defect.

Given this conflicting and relatively small literature, as well as the difficulty accounting for confounders, the risk of bupropion exposure versus nontreatment should be considered carefully, as with any medication in pregnancy. Patients should be counseled that bupropion and its metabolites have been found to cross the placenta,<sup>85</sup> but this should factor be weighed against the risks of depression or smoking for the patient and the baby.

A review of the literature on mirtazapine in pregnancy and lactation included 31 papers with 390 cases of neonates, and concluded that mirtazapine is not associated with increased risk of malformations; however, there was not enough information to make any conclusions on risks of mirtazapine during lactation.<sup>86</sup> Of note, typical exposure through lactation involves even more factors, such as amount in the mother's blood, protein binding and oral bioavailability,<sup>87</sup> which often manifests as reduced transfer to the newborn.

### **TRICYCLIC ANTIDEPRESSANTS, MONOAMINE OXIDASE INHIBITORS, AND TRAZODONE**

Tricyclic antidepressants (TCAs), first discovered in the 1950s, revolutionized the treatment of depression and preceded SSRIs.<sup>88</sup> TCAs are associated with higher mortality rates owing to overdose.<sup>89</sup> Monoamine oxidase inhibitors were also first discovered in the 1950s.<sup>88</sup> There is very little data on monoamine oxidase inhibitors.<sup>90</sup> Trazodone also has limited data. All 3 agents are discussed in **Table 1**. Limb anomalies in earlier studies of TCAs have not been confirmed and neonatal behavioral effects



from fetal exposure have not been reported.<sup>91</sup> Monoamine oxidase inhibitors included in a study with other antidepressants did not identify adverse fetal outcomes.<sup>92</sup> A study of 147 women taking nefazadone or trazodone were compared with 2 other groups—women taking other antidepressants or women taking another nonpsychotropic medication thought to be nonteratogenic—and found no differences in the rate of major malformations.<sup>93</sup> Conceivably, the same concerns as for SSRIs may be present, such as for possible increased risk of PPHN.<sup>94</sup> Similar to SSRIs, neonatal symptoms, such as transient withdrawal symptoms, have been reported.<sup>91</sup> TCAs studied in the Quebec Pregnancy Cohort were associated with eye, ear, face, neck, and digestive defects, although the confidence interval for the eye, ear, face, and neck defects was very close to 1.0.<sup>95</sup> Several cohorts of exposed children have been followed with no identified negative neurobehavioral effects of TCAs.<sup>96–98</sup>

### **AUGMENTATION MEDICATIONS (LITHIUM, ATYPICAL ANTIPSYCHOTICS, AND LAMOTRIGINE)**

See **Table 1** for more details about lithium, atypical antipsychotics and lamotrigine used for augmentation. Recent literature has shown that lithium's association with cardiac malformations is smaller than previously thought,<sup>99</sup> and must be weighed against the risks of the illness itself. Although limited, data for lithium and second-generation antipsychotics indicate effects are reassuring with regards to child development.<sup>100</sup> Despite some earlier concerns, subsequent studies have suggested that lamotrigine is not associated with an increased risk of congenital malformations.<sup>101</sup> The long-term safety profile of lamotrigine during pregnancy is promising. In a review that included 8 studies, lamotrigine had no adverse outcomes on infant IQ or neurodevelopment.<sup>102</sup>

### **NEW DEVELOPMENTS IN DRUG SAFETY LABELING AND MONITORING**

This review does not include information on the FDA pregnancy risk categories (A, B, C, D, and X), which began in 1979.<sup>103</sup> This labeling system has been criticized for not adequately reflecting the complexity of decision making about medication use during pregnancy. This system is not conducive to assessing relative risk within categories, has often been viewed as hierarchical rather than descriptive, and does not readily allow for updating based on new findings.<sup>103,104</sup>

In December 2014, the FDA published the Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling, also referred to as the “Pregnancy and Lactation Labeling Rule.” The rule was implemented on June 30, 2015. It requires medication labels to include a risk summary and clinical considerations, including information relevant for decision making, such as the risk of untreated conditions, complications, and interventions, and data. It prioritizes the inclusion of new information available from drug registries and postmarketing surveillance. Medications approved after 2001 will be required to implement this new labeling by June of 2020, and those approved before 2001, to remove letter ratings by June 30, 2018.<sup>103,105</sup> More information is available at <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.html>.

### **ESTRADIOL AND PROGESTIN TREATMENTS**

Many investigators have hypothesized that alterations in reproductive hormones contribute to PPD because of the temporal association between the precipitous

decrease in hormone concentrations that occur with childbirth and the onset of mood symptoms.<sup>106</sup> Reproductive hormones have been shown to play a role in basic emotion processing, arousal, cognition, and motivation, and they regulate each of the biological systems implicated in depression (eg, thyroid, immune, and hypothalamic–pituitary–adrenal axis function and genetic expression).<sup>32</sup> Reproductive hormones also regulate neurotransmitter synthesis, release, and transport, impacting the neural systems implicated in depression.<sup>32</sup> Experimental studies have shown that some women with a history of PPD are differentially sensitive to the effects of changes of estrogen and progesterone on mood.<sup>107</sup> One pilot study of pregnant women with a history of PPD showed that prophylactic administration of oral Premarin, a conjugated estrogen, prevented PPD recurrence in 10 of the 11 women studied.<sup>108</sup> A later double-blind, placebo-controlled trial of 61 women with PPD that began within 3 months after delivery showed that women treated with transdermal estradiol ( $n = 34$ ) showed a greater decrease in depressive symptoms than those who received placebo ( $n = 27$ ), although almost one-half of the women in each group were also taking antidepressants.<sup>109</sup> Finally, another study of 23 women with severe PPD, many of whom had not experienced benefit from treatment with either antidepressant medication or psychotherapy, and were found to have low concentrations of serum estradiol, were considered to be in “gonadal failure,” and showed symptom remission after 8 weeks of sublingual estrogen treatment.<sup>110</sup> Estradiol may be an effective treatment for PPD; however, a large RCT is needed before recommending hormonal treatment in the postpartum period given the known risks of impaired lactation and venous thromboembolism with oral estrogen preparations. The only large-scale RCT to date was stopped early after finding that treatment with 200  $\mu\text{g}$  transdermal estradiol did not result in significantly increased serum estradiol concentrations.<sup>111</sup> There is even less evidence for progesterone treatment for PPD. One study found norethisterone enanthate, a synthetic progestogen, administered within 48 hours of delivery, was associated with a significantly higher risk of developing PPD.<sup>112</sup> Of note, in a small study of nonpregnant women across the spectrum from anorexia nervosa to normal weight to obese, progesterone levels were not associated with depressive or anxiety symptoms; however, allopregnanolone levels were.<sup>113</sup> Intravenous allopregnanolone therapy is promising and discussed in the Future Directions section.

## GENERAL RULES OF THUMB AND TREATMENT ALGORITHM


The rule of thumb for treating perinatal women is that one size does not fit all, and each patient should have an individualized discussion with her provider about the risks of medication weighed against her own risks of not taking medication during pregnancy or lactation. Women who decide they want to come off medications should do so with the supervision of a physician, and ideally preconceptionally. Abrupt medication discontinuation has been associated with high relapse rates. In a prospective sample of 201 euthymic women on stable doses of antidepressants at the time of conception, 68% who discontinued medications during pregnancy experienced relapse of symptoms, and 60% of those who stopped their medication restarted it later in pregnancy.<sup>114</sup> Predictors of relapse included having 4 or more prior depressive episodes and suffering illness for more than 5 years.<sup>114</sup> The most judicious approach is to use the least amount of medication that helps a woman feel better and keeps her well. As noted, it is important to recognize that higher dosages are often required than pre-pregnancy dosages owing to increased blood volume and increased metabolism during pregnancy. Managing sleep and comorbidities, while providing a multidisciplinary treatment approach, will improve outcomes with medication treatment of perinatal depression.

Breastfeeding is promoted by all major medical groups for the first year of the child's life to improve both maternal and infant health outcomes.<sup>115</sup> Therefore, to minimize stress on the mother, for most medications pumping and dumping (ie, pumping and then throwing out all milk while taking a medication or after taking the medication throwing out the first pump of milk after taking the medication) is not advised.<sup>87</sup> However, there may be cases where the risk–benefit ratio supports this practice, such as in the case of a treatment agent that may have high likelihood of passing into breast milk. As noted, the amount of medication exposure in breast milk is thought to be far less than exposure during pregnancy through transplacental passage. Data from the National Institutes of Health have demonstrated that SSRIs are compatible with breastfeeding.<sup>74</sup> It is important to collaborate with the infant's pediatrician when a mother is taking a psychotropic medication during lactation, and to monitor the infant for sedation, proper weight gain, and achievement of developmental milestones. For any medication other than lithium, the literature does not support checking infant blood levels.<sup>116</sup> For questions, an important resource is LACTMED, <https://toxnet.nlm.nih.gov/newtoxnet/lactmed.html>, a database from the National Institutes of Health, with information on medication patients may have taken during pregnancy.

We have developed a treatment algorithm based on the literature and the clinical experience of our perinatal psychiatry team (**Fig. 1**). For a patient who has not tried medication before, sertraline is a good first choice given it is often well-tolerated, has efficacy for anxiety symptoms along with depressive symptoms, is an older medication with a relatively large evidence base, and has low breast milk concentrations in mother–infant dyad studies.<sup>116</sup> In general, medications that are less lipophilic, with shorter half-lives, are less likely to cross the placenta or cross into breast milk. However, if a patient is doing well with, or has done well with, another type of antidepressant, then it is better to continue with that medication, especially if other medications have not been effective for the patient. Alternatively, if a patient is not responding to a medication, it is important to consider other complicating factors and rethink the diagnosis. For STAR\*D participants with major depression (general outpatients including men and women ages 18–75), severity, poor treatment adherence, and poor physical health increased the risk of depression failing to, or taking a longer time to remit. Social factors such as unemployment was also associated with nonremission.<sup>117</sup> Clinicians must also carefully screen for history of mania or hypomania to rule out bipolar spectrum illness, as a different treatment algorithm should then be applied, and antidepressants could significantly worsen symptoms if used alone.<sup>2,35,118,119</sup> Those presenting with first episodes of depression in the postpartum period are more likely to develop bipolar affective disorder and psychotic symptoms.<sup>120</sup> In addition, those with bipolar disorders I or II are associated with PPD rates as high as 50%.<sup>121</sup> The psychosis specifier of major depressive disorder is found more often in women who are postpartum than in those with depressive episodes during pregnancy, as well as nonpregnant women.<sup>122,123</sup> Psychotic symptoms can sometimes be hard to gather, so spending some time talking with patients and with their family and supports will help to identify those symptoms. If there is a question of psychosis, emergency referral to perinatal psychiatry is important.

## FUTURE DIRECTIONS FOR PHARMACOLOGIC TREATMENT OF PERINATAL DEPRESSION

There is new evidence that the neurosteroid, allopregnanolone, a major metabolite of progesterone, may potentially contribute to the etiology and treatment of PPD.<sup>32,124</sup> Allopregnanolone is a positive allosteric modulator of synaptic and extrasynaptic GABA-A receptors<sup>125,126</sup> and animal models have demonstrated that it has significant



**Fig. 1.** Treatment algorithm for perinatal depression. MAOI, monoamine oxidase inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.

effects on anxiety and depression.<sup>32</sup> Allopregnanolone concentrations rapidly decrease after childbirth, after reaching peak physiologic levels in the third trimester of pregnancy.<sup>32,124</sup> It is hypothesized that the failure of GABA-A receptors to adapt to the rapid fluctuations at childbirth may be a trigger for PPD.<sup>127–130</sup> This line of inquiry is being explored by the development of brexanolone, a proprietary formulation of allopregnanolone as a treatment for PPD. A positive small open-label trial,<sup>131</sup> and more recently, a positive phase II RCT of brexanolone showed rapid and clinically meaningful reductions in depressive symptoms as compared with placebo.<sup>132</sup> Sage Therapeutics (Cambridge, MA) announced in November 2017 that they obtained statistically significant mean reduction depressive symptoms with brexanolone compared with placebo at 60 hours, and was durable over 30 days in 2 placebo-controlled multicenter phase III trials.<sup>133</sup>

Another possible novel area of intervention may be the microbiota–gut–brain axis. Preliminary findings from an RCT testing the use of a probiotics in pregnancy warrant further study with regard to depressive and anxiety symptoms.<sup>134,135</sup> Although there is

no evidence as of yet to support the use of probiotic pills, the gut microbiota may be an important mediator of antidepressant effects given that certain microbes are involved in tryptophan and serotonin metabolism, and in drug metabolism.<sup>136,137</sup> Additional microbiome research may allow for better understanding of how medications are metabolized and best used during the perinatal period.

There is great need for innovative models regarding delivery of care to perinatal women. The literature demonstrates that only a small percentage of perinatal women are adequately screened and treated for perinatal depression<sup>5,138</sup> owing to multiple barriers.<sup>139</sup> Integrated care models that embed mental health providers in obstetric settings and specialized perinatal psychiatry inpatient units may further ensure patients better access and care.<sup>140</sup>

## SUMMARY

Perinatal depression is a treatable medical condition. There are many evidence-based treatments, but novel treatment paradigms are also needed to target the underlying pathogenesis of perinatal depression and to increase the efficacy of treatment. Treatment can have important reductions in suffering for women and their families.

## REFERENCES

1. World Health Organisation. ICD-10 classifications of mental and behavioural disorder: clinical descriptions and diagnostic guidelines. 1992.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. Arlington (VA): American Psychiatric Publishing; 2013.
3. Gaynes B, Gavin N, Meltzer-Brody S. Perinatal depression: prevalence, screening accuracy and screening outcomes. *Evid Rep Technol Assess* 2005; 119:1–8.
4. Elisei S, Lucarini E, Murgia N, et al. Perinatal depression: a study of prevalence and of risk and protective factors. *Psychiatr Danub* 2013;25:S258–62.
5. Cox EQ, Sowa NA, Meltzer-Brody SE, et al. The perinatal depression treatment cascade: baby steps toward improving outcomes. *J Clin Psychiatry* 2016;77(9): 1189–200.
6. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. *J Clin Psychiatry* 2013;74(4):321–41.
7. Herring SJ, Rich-Edwards JW, Oken E, et al. Association of postpartum depression with weight retention 1 year after childbirth. *Obesity* 2008;16:1296–301.
8. Qiu C, Williams MA, Calderon-Margalit R, et al. Preeclampsia risk in relation to maternal mood and anxiety disorders diagnosed before or during early pregnancy. *Am J Hypertens* 2009;22:397–402.
9. Meltzer-Brody S, Bledsoe-Mansori SE, Johnson N, et al. A prospective study of perinatal depression and trauma history in pregnant minority adolescents. *Am J Obstet Gynecol* 2013;208(211):e1–7.
10. Milgrom J, Gemmill AW, Bilszta JL, et al. Antenatal risk factors for postnatal depression: a large prospective study. *J Affect Disord* 2008;108:147–57.
11. Garner AS, Shonkoff JP, Committee on Psychosocial Aspects of Child and Family Health, Committee on Early Childhood, Adoption, and Dependent Care, Section on Developmental and Behavioral Pediatrics. Early childhood adversity, toxic stress, and the role of the pediatrician: translating developmental science into lifelong health. *Pediatrics* 2012;129(1):e224–31.

12. Earls MF, T.C.o.P.A.o.C.a.F. Health. Clinical report – Incorporating recognition and management of perinatal and postpartum depression into pediatric practice American Academy of Pediatrics, 2010.
13. Shonkoff JP, Garner AS, Committee on Psychosocial Aspects of Child and Family Health, Committee on Early Childhood, Adoption, and Dependent Care, Section on Developmental and Behavioral Pediatrics. The lifelong effects of early childhood adversity and toxic stress. *Pediatrics* 2012;129(1):e232–46.
14. National Scientific Council on the Developing Child, Center on the Developing Child at Harvard University. Excessive stress disrupts the architecture of the developing brain: paper #3. Cambridge (MA): National Scientific Council on the Developing Child, Center on the Developing Child at Harvard University; 2005.
15. National Scientific Council on the Developing Child. Early Experiences Can Alter Gene Expression and Affect Long-Term Development: Working Paper #10 2010. Available at: <http://www.developingchild.net>.
16. Dawson G, Ashman S. On the origins of a vulnerability to depression: the influence of the early social environment on the development of psychobiological systems related to risk for affective disorder. In: Nelson C, editor. The effects of adversity on neurobehavioral development: Minnesota symposium on child psychology. Mahwah (NJ): Lawrence Erlbaum & Assoc; 2000. p. 245–80.
17. Ashman S, Dawson G, Panagiotides H, et al. Stress hormone levels of children of depressed mothers. *Dev Psychopathol* 2002;14(2):333–49.
18. Essex MJ, Klein MH, Cho E, et al. Maternal stress beginning in infancy may sensitize children to later stress exposure: effects on cortisol and behavior. *Biol Psychiatry* 2002;52(8):776–84.
19. Dennis C, McQueen K. The relationship between infant-feeding outcomes and postpartum depression: a qualitative systematic review. *Pediatrics* 2009;123(4):736–51.
20. Woolhouse H, Gartland D, Mensah F, et al. Maternal depression from early pregnancy to 4 years postpartum in a prospective pregnancy cohort study: implications for primary health care. *BJOG* 2014. <https://doi.org/10.1111/1471-0528.12837>.
21. Lindahl V, Pearson J, Colpe L. Prevalence of suicidality during pregnancy and postpartum. *Arch Womens Ment Health* 2005;8(2):77–87.
22. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. *Gen Hosp Psychiatry* 2009;31:403–13.
23. Battle CL, Salisbury AL, Schofield CA, et al. Perinatal antidepressant use: understanding women's preferences and concerns. *J Psychiatr Pract* 2013;19(6):443–53.
24. Goodman JH. Women's attitudes, preferences, and perceived barriers to treatment for perinatal depression. *Birth* 2009;36(1):60–9.
25. Claridge AM. Efficacy of systematically oriented psychotherapies in the treatment of perinatal depression: a meta analysis. *Arch Womens Ment Health* 2014;17:3–15.
26. Grote NK, Swartz HA, Geibel SL, et al. A randomized controlled trial of culturally relevant, brief interpersonal psychotherapy for perinatal depression. *Psychiatr Serv* 2009;60(3):313–21.

27. Spinelli MG, Endicott J, Leon AC, et al. A controlled clinical treatment trial of interpersonal psychotherapy for depressed pregnant women at 3 New York City sites. *J Clin Psychiatry* 2013;74(4):393–9.
28. Sockol LE, Epperson CN, Barber JP. A meta-analysis of treatments for perinatal depression. *Clin Psychol Rev* 2011;31(5):839–49.
29. O'Hara MW, McCabe JE. Postpartum depression: current status and future directions. *Annu Rev Clin Psychol* 2013;9:379–407.
30. Wisner KL, Zarin DA, Holmboe ES, et al. Risk-benefit decision making for treatment of depression during pregnancy. *Am J Psychiatry* 2000;157(12):1933–40.
31. O'Hara M, Swain AW. Rates and risk of postpartum depression—a meta-analysis. *Int Rev Psychiatry* 1996;8(1):37–54.
32. Schiller CE, Meltzer-Brody S, Rubinow DR. The role of reproductive hormones in postpartum depression. *CNS Spectr* 2015;20(1):48–59.
33. FDA, Medication Guides, 2017, U.S. Department of Health and Human Services.
34. Weisskopf E, Fischer CJ, Bickle Graz M, et al. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence. *Expert Opin Drug Saf* 2015;14(3):413–27.
35. Mann J. The medical management of depression. *N Engl J Med* 2005;353(17):1819–34.
36. Kroenke K, West SL, Swindle R. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. *JAMA* 2001;286:2947–55.
37. Stahl S. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. *Biol Psychiatry* 2000;48:894–901.
38. Huybrechts KF, Sanghani RS, Avorn J, et al. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. *PLoS One* 2014;9(3):e92778.
39. Andersen JT, Andersen NL, Horwitz H, et al. Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage. *Obstet Gynecol* 2014;124(4):655–61.
40. Sujan AC, Rickert ME, Oberg AS, et al. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. *JAMA* 2017;317(15):1553–62.
41. Liu X, Agerbo E, Ingstrup KG, et al. Antidepressant use during pregnancy and psychiatric disorders in offspring: Danish nationwide register based cohort study. *BMJ* 2017;358:j3668.
42. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. *N Engl J Med* 2014;370(25):2397–407.
43. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med* 2006;354(6):579–87.
44. Wilson KL, Zelig CM, Harvey JP, et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. *Am J Perinatol* 2011;28(1):19–24.
45. US Food and Drug Administration (FDA). FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. 2011. Available at: <https://http://www.fda.gov/Drugs/DrugSafety/ucm283375.htm>. Accessed October 20, 2017.

46. Huybrechts KF, Bateman BT, Palmsten K, et al. Antidepressant use in late pregnancy and risk of persistent pulmonary hypertension of the newborn. *JAMA* 2015;313(21):2142–51.
47. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. *Arch Pediatr Adolesc Med* 2006;160(2):173–6.
48. Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. *J Clin Psychiatry* 2004;65(2):230–7.
49. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. *JAMA* 2005;293(19):2372–83.
50. Forsberg L, Navér L, Gustafsson LL, et al. Neonatal adaptation in infants prenatally exposed to antidepressants- clinical monitoring using neonatal abstinence score. *PLoS One* 2014;9(11):e111327.
51. Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. *Acta Psychiatr Scand* 2010;121(6):471–9.
52. Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: how about the newborn? *Neuropsychiatr Dis Treat* 2013;9:1257–66.
53. Nulman I, Koren G, Rovet J, et al. Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling study. *J Clin Psychiatry* 2015;76(7):e842–7.
54. Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. *Arch Gen Psychiatry* 2011;68(11):1104–12.
55. Rai D, Lee BK, Dalman C, et al. Parental depression, maternal antidepressant use during pregnancy, and the risk of autism spectrum disorders: population based case-control study. *BMJ* 2013;346:f2059.
56. Boukhris T, Sheehy O, Mottron L, et al. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. *JAMA Pediatr* 2016;170(2):117–24.
57. Andrade C. Antidepressant exposure during pregnancy and risk of autism in the offspring, 1: meta-review of meta-analyses. *J Clin Psychiatry* 2017;78(8):e1047–51.
58. Castro VM, Kong SW, Clements CC, et al. Absence of evidence for increase in risk for autism or attention-deficit hyperactivity disorder following antidepressant exposure during pregnancy: a replication study. *Transl Psychiatry* 2016;6:e708.
59. Oberlander TF, Gingrich JA, Ansorge MS. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. *Clin Pharmacol Ther* 2009;86(6):672–7.
60. Wisner KL, Bogen DL, Sit D, et al. Does fetal exposure to SSRIs or maternal depression impact infant growth? *Am J Psychiatry* 2013;170(5):485–93.
61. Santucci AK, Singer LT, Wisniewski SR, et al. Impact of prenatal exposure to serotonin reuptake inhibitors or maternal major depressive disorder on infant developmental outcomes. *J Clin Psychiatry* 2014;75(10):1088–95.
62. Rush A, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR\*D): rationale and design. *Control Clin Trials* 2004;25(1):119–42.



63. Gaynes BN, Warden D, Trivedi MH, et al. What did STAR\*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. *Psychiatr Serv* 2009;60(11):1439–45.
64. Lambert O, Bourin M. SNRIs: mechanism of action and clinical features. *Expert Rev Neurother* 2002;2(6):849–58.
65. Laurent L, Huang C, Ernest SR, et al. In utero exposure to venlafaxine, a serotonin-norepinephrine reuptake inhibitor, increases cardiac anomalies and alters placental and heart serotonin signaling in the rat. *Birth Defects Res A Clin Mol Teratol* 2016;106(12):1044–55.
66. Selmer R, Haglund B, Furu K, et al. Individual-based versus aggregate meta-analysis in multi-database studies of pregnancy outcomes: the Nordic example of selective serotonin reuptake inhibitors and venlafaxine in pregnancy. *Pharmacoepidemiol Drug Saf* 2016;25(10):1160–9.
67. Bellantuono C, Vargas M, Mandarelli G, et al. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. *Hum Psychopharmacol* 2015;30(3):143–51.
68. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. *Am J Psychiatry* 2001;158(10):1728–30.
69. Lassen D, Ennis ZN, Damkier P. First-trimester pregnancy exposure to venlafaxine or duloxetine and risk of major congenital malformations: a systematic review. *Basic Clin Pharmacol Toxicol* 2016;118(1):32–6.
70. Einarson A, Smart K, Vial T, et al. Rates of major malformations in infants following exposure to duloxetine during pregnancy: a preliminary report. *J Clin Psychiatry* 2012;73(11):1471.
71. Berard A, Sheehy O, Zhao JP, et al. SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn. *Br J Clin Pharmacol* 2017;83(5):1126–33.
72. Ewing G, Tatarchuk Y, Appleby D, et al. Placental transfer of antidepressant medications: implications for postnatal adaptation syndrome. *Clin Pharmacokinet* 2015;54(4):359–70.
73. Holland J, Brown R. Neonatal venlafaxine discontinuation syndrome: a mini-review. *Eur J Paediatr Neurol* 2017;21(2):264–8.
74. National Institutes of Health. TOXNET Toxicology Data Network. Available at: <https://toxnet.nlm.nih.gov>. Accessed October 20, 2017.
75. Kumari A, Singh M, Trigunayat A, et al. Prenatal desvenlafaxine induced behavioral alterations in Swiss albino mice. *Ann Neurosci* 2014;21(1):19–21.
76. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. *Lancet* 2016;387(10037):2507–20.
77. Hughes JR, Stead LF, Hartmann-Boyce J, et al. Antidepressants for smoking cessation. *Cochrane Database Syst Rev* 2014;(1):CD000031.
78. Baraona LK, Lovelace D, Daniels JL, et al. Tobacco harms, nicotine pharmacology, and pharmacologic tobacco cessation interventions for women. *J Midwifery Womens Health* 2017;62(3):253–69.
79. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. *CNS Drug Rev* 2001;7(3):249–64.
80. Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression. *Cochrane Database Syst Rev* 2011;(12):CD006528.

81. Cole JA, Modell JG, Haight BR, et al. Bupropion in pregnancy and the prevalence of congenital malformations. *Pharmacoepidemiol Drug Saf* 2007;16(5):474–84.
82. Thyagarajan V, Robin Clifford C, Wurst KE, et al. Bupropion therapy in pregnancy and the occurrence of cardiovascular malformations in infants. *Pharmacoepidemiol Drug Saf* 2012;21(11):1240–2.
83. Alwan S, Reefhuis J, Botto LD, et al. Maternal use of bupropion and risk for congenital heart defects. *Am J Obstet Gynecol* 2010;203(1):52.e1-6.
84. Louik C, Kerr S, Mitchell AA. First-trimester exposure to bupropion and risk of cardiac malformations. *Pharmacoepidemiol Drug Saf* 2014;23(10):1066–75.
85. Fokina VM, West H, Oncken C, et al. Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. *Am J Obstet Gynecol* 2016;215(4):497.e1-7.
86. Smit M, Dolman KM, Honig A. Mirtazapine in pregnancy and lactation - A systematic review. *Eur Neuropsychopharmacol* 2016;26(1):126–35.
87. Burkey BW, Holmes AP. Evaluating medication use in pregnancy and lactation: what every pharmacist should know. *J Pediatr Pharmacol Ther* 2013;18(3):247–58.
88. Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. *Curr Pharm Des* 2009;15(14):1563–86.
89. Carvalho AF, Sharma MS, Brunoni AR, et al. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. *Psychother Psychosom* 2016;85(5):270–88.
90. Gracious BL, Wisner KL. Phenelzine use throughout pregnancy and the puerperium: case report, review of the literature, and management recommendations. *Depress Anxiety* 1997;6(3):124–8.
91. ACOG Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. *Obstet Gynecol* 2008;111(4):1001–20.
92. Ramos E, St-André M, Rey E, et al. Duration of antidepressant use during pregnancy and risk of major congenital malformations. *Br J Psychiatry* 2008;192(5):344–50.
93. Einarson A, Bonari L, Voyer-Lavigne S, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. *Can J Psychiatry* 2003;48(2):106–10.
94. Ram D, Gandotra S. Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation. *Indian J Psychiatry* 2015;57(Suppl 2):S354–71.
95. Berard A, Zhao JP, Sheehy O. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. *BMJ Open* 2017;7(1):e013372.
96. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. *N Engl J Med* 1997;336(4):258–62.
97. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. *Am J Psychiatry* 2002;159(11):1889–95.
98. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. *Am J Psychiatry* 2002;159(12):2055–61.

99. Patorno E, Huybrechts KF, Bateman BT, et al. Lithium use in pregnancy and the risk of cardiac malformations. *N Engl J Med* 2017;376(23):2245–54.
100. Haskey C, Galbally M. Mood stabilizers in pregnancy and child developmental outcomes: a systematic review. *Aust N Z J Psychiatry* 2017;51(11):1087–97.
101. Bromley RL, Weston J, Marson AG. Maternal use of antiepileptic agents during pregnancy and major congenital malformations in children. *JAMA* 2017;318(17):1700–1.
102. Ornoy A, Weinstein-Fudim L, Ergaz Z. Antidepressants, antipsychotics, and mood stabilizers in pregnancy: what do we know and how should we treat pregnant women with depression. *Birth Defects Res* 2017;109(12):933–56.
103. Ramoz LL, Patel-Shori NM. Recent changes in pregnancy and lactation labeling: retirement of risk categories. *Pharmacotherapy* 2014;34(4):389–95.
104. Dinatale M, Sahin L, Johnson T, et al. Medication use during pregnancy and lactation: introducing the pregnancy and lactation labeling rule. *Pediatr Allergy Immunol Pulmonol* 2017;30(2):132–4.
105. Whyte J. FDA implements new labeling for medications used during pregnancy and lactation. *Am Fam Physician* 2016;94(1):12–5.
106. O'Hara MW, Schlechte JA, Lewis DA, et al. Controlled prospective study of postpartum mood disorders: psychological, environmental, and hormonal variables. *J Abnorm Psychol* 1991;100(1):63–73.
107. Bloch M, Schmidt PJ, Danaceau M, et al. Effects of gonadal steroids in women with a history of postpartum depression. *Am J Psychiatry* 2000;157(6):924–30.
108. Sichel DA, Cohen LS, Robertson LM, et al. Prophylactic estrogen in recurrent postpartum affective disorder. *Biol Psychiatry* 1995;38(12):814–8.
109. Gregoire AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for treatment of severe postnatal depression. *Lancet* 1996;347(9006):930–3.
110. Ahokas A, Kaukoranta J, Wahlbeck K, et al. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study. *J Clin Psychiatry* 2001;62(5):332–6.
111. Wisner KL, Sit DK, Moses-Kolko EL, et al. Transdermal estradiol treatment for postpartum depression: a pilot, randomized trial. *J Clin Psychopharmacol* 2015;35(4):389–95.
112. Lawrie TA, Hofmeyr GJ, De Jager M, et al. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. *Br J Obstet Gynaecol* 1998;105(10):1082–90.
113. Dichtel LE, Lawson EA, Schorr M, et al. Neuroactive steroids and affective symptoms in women across the weight spectrum. *Neuropsychopharmacology* 2018;43(6):1436–44.
114. Cohen LS, Altschuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. *JAMA* 2006;295(5):499–508.
115. Section on Breastfeeding. Breastfeeding and the use of human milk. *Pediatrics* 2012;129(3):e827–41.
116. Pinheiro E, Bogen DL, Hoxha D, et al. Sertraline and breastfeeding: review and meta-analysis. *Arch Womens Ment Health* 2015;18(2):139–46.
117. Mojtabai R. Nonremission and time to remission among remitters in major depressive disorder: revisiting STAR\*D. *Depress Anxiety* 2017;34(12):1123–33.
118. First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV-TR axis I disorders, research version, non-patient edition (SCID-I/NP). New York: N.Y.S.P.I. Biometrics Research; 2002.

119. Patel R, Reiss P, Shetty H, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. *BMJ* 2015;5(12):e008341.
120. Azorin JM, Angst J, Gamma A, et al. Identifying features of bipolarity in patients with first-episode postpartum depression: findings from the international BRIDGE study. *J Affect Disord* 2012;136(3):710–5.
121. Mandelli L, Souery D, Bartova L, et al. Bipolar II disorder as a risk factor for postpartum depression. *J Affect Disord* 2016;204:54–8.
122. Altemus M, Neeb CC, Davis A, et al. Phenotypic differences between pregnancy-onset and postpartum-onset major depressive disorder. *J Clin Psychiatry* 2012;73(12):e1485–91.
123. Dean C, Kendell RE. The symptomatology of puerperal illnesses. *Br J Psychiatry* 1981;139:128–33.
124. Epperson CN, Gueorgieva R, Czarkowski KA, et al. Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. *Psychopharmacology (Berl)* 2006;186(3):425–33.
125. Paul SM, Purdy RH. Neuroactive steroids. *FASEB J* 1992;6(6):2311–22.
126. Majewska MD, Harrison NL, Schwartz RD, et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. *Science* 1986;232(4753):1004–7.
127. Deligiannidis KM, Kroll-Desrosiers AR, Mo S, et al. Peripartum neuroactive steroid and  $\gamma$ -aminobutyric acid profiles in women at-risk for postpartum depression. *Psychoneuroendocrinology* 2016;70:98–107.
128. Nappi RE, Petraglia F, Luisi S, et al. Serum allopregnanolone in women with postpartum “blues”. *Obstet Gynecol* 2001;97(1):77–80.
129. Luisi S, Petraglia F, Benedetto C, et al. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. *J Clin Endocrinol Metab* 2000;85(7):2429–33.
130. Maguire J, Mody I. GABA(A)R plasticity during pregnancy: relevance to postpartum depression. *Neuron* 2008;59(2):207–13.
131. Kanes SJ, Colquhoun H, Doherty J, et al. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. *Hum Psychopharmacol* 2017;32(2):e2576, 1–6.
132. Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. *Lancet* 2017;390(10093):480–9.
133. Sage therapeutics announces brexanolone achieves primary endpoints in both phase 3 clinical trials in postpartum depression. 2017. Available at: <http://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-brexanolone-achieves-primary>. Accessed October 20, 2017.
134. Barthow C, Wickens K, Stanley T, et al. The Probiotics in Pregnancy Study (PiP Study): rationale and design of a double-blind randomised controlled trial to improve maternal health during pregnancy and prevent infant eczema and allergy. *BMC Pregnancy Childbirth* 2016;16(1):133.
135. Slykerman RF, Hood F, Wickens K, et al. Effect of *Lactobacillus rhamnosus* HN001 in pregnancy on postpartum symptoms of depression and anxiety: a randomised double-blind placebo-controlled trial. *EBioMedicine* 2017;24:159–65.
136. O'Mahony SM, Clarke G, Borre YE, et al. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. *Behav Brain Res* 2015;277:32–48.

137. Gimenez-Bastida JA, Martinez Carreras L, Moya-Pérez A, et al. Pharmacological efficacy/toxicity of drugs: a comprehensive update about the dynamic interplay of microbes. *J Pharm Sci* 2018;107(3):778–84.
138. Fonseca A, Gorayeb R, Canavarro MC. Womens help-seeking behaviours for depressive symptoms during the perinatal period: socio-demographic and clinical correlates and perceived barriers to seeking professional help. *Midwifery* 2015;31(12):1177–85.
139. Bayrampour H, McNeil DA, Benzies K, et al. A qualitative inquiry on pregnant women's preferences for mental health screening. *BMC Pregnancy Childbirth* 2017;17(1):339.
140. Cox EQ, Raines C, Kimmel M, et al. Comprehensive integrated care model to improve maternal mental health. *J Obstet Gynecol Neonatal Nurs* 2017;46(6):923–30.
141. GlaxoSmithKline. New safety information regarding paroxetine: findings suggest increased risk over other antidepressants, of congenital malformations, following first trimester exposure to paroxetine. Mississauga (Canada): GlaxoSmithKline; 2005.
142. Laughren T. Approval package for: application number NDA 20-031/S052. FDA; 2006.
143. Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. *Pain* 2004;110:697–706.
144. Nanovskaya TN, Oncken C, Fokina VM, et al. Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial. *Am J Obstet Gynecol* 2017;216(4):420.e1–9.
145. Berard A, Zhao JP, O Sheehy. Success of smoking cessation interventions during pregnancy. *Am J Obstet Gynecol* 2016;215(5):611.e1-8.
146. Abramowitz A, Miller ES, Wisner KL. Treatment options for hyperemesis gravidarum. *Arch Womens Ment Health* 2017;20(3):363–72.
147. Omay O, Einarson A. Is mirtazapine an effective treatment for nausea and vomiting of pregnancy? A case series. *J Clin Psychopharmacol* 2017;37(2):260–1.
148. Khazaie H, Ghadami MR, Knight DC, et al. Insomnia treatment in the third trimester of pregnancy reduces postpartum depression symptoms: a randomized clinical trial. *Psychiatry Res* 2013;210(3):901–5.
149. Wichman CL, Stern TA. Diagnosing and treating depression during pregnancy. *Prim Care Companion CNS Disord* 2015;17(2):1–11.
150. Nonacs R, Cohen LS. Assessment and treatment of depression during pregnancy: an update. *Psychiatr Clin North Am* 2003;26(3):547–62.
151. Rihmer Z, Gonda X, Rihmer A, et al. Antidepressant-resistant depression and the bipolar spectrum – diagnostic and therapeutic considerations. *Psychiatr Hung* 2016;31(2):157–68 [in Hungarian].
152. Barbee JG, Thompson TR, Jamhour NJ, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. *J Clin Psychiatry* 2011;72(10):1405–12.
153. Bruno A, Micò U, Pandolfo G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. *J Psychopharmacol* 2012;26(11):1456–62.
154. Khalkhali M, Aram S, Zarrabi H, et al. Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial. *Iran J Psychiatry* 2016;11(2):104–14.

155. O'Hara MW, Wisner KL. Perinatal mental illness: definition, description and aetiology. *Best Pract Res Clin Obstet Gynaecol* 2014;28(1):3–12.
156. Naguy A, Al-Enezi N. Lamotrigine uses in psychiatric practice-beyond bipolar prophylaxis a hope or hype? *Am J Ther* 2017. [Epub ahead of print].
157. Mohamed S, Johnson GR, Chen P, et al. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. *JAMA* 2017;318(2):132–45.
158. Sharma V, Smith A, Mazmanian D. Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder. *Bipolar Disord* 2006;8(4):400–4.
159. Baastrup PC, Schou M. Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. *Arch Gen Psychiatry* 1967;16(2):162–72.
160. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR\*D report. *Am J Psychiatry* 2006;163(11):1905–17.
161. Bergink V, Burgerhout KM, Koorengevel KM, et al. Treatment of psychosis and mania in the postpartum period. *Am J Psychiatry* 2015;172(2):115–23.
162. Bergink V, Bouvy PF, Vervoort JS, et al. Prevention of postpartum psychosis and mania in women at high risk. *Am J Psychiatry* 2012;169(6):609–15.
163. Austin MP. Puerperal affective psychosis: is there a case for lithium prophylaxis? *Br J Psychiatry* 1992;161:692–4.
164. Cohen LS, Sichel DA, Robertson LM, et al. Postpartum prophylaxis for women with bipolar disorder. *Am J Psychiatry* 1995;152(11):1641–5.
165. Wisner KL, Hanusa BH, Peindl KS, et al. Prevention of postpartum episodes in women with bipolar disorder. *Biol Psychiatry* 2004;56(8):592–6.